¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"drug intolerance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® intolerance ÇÑ±Û ¸ø°ßµõ(Áõ)
¼³¸í   
  »ó¿ë·®ÀÇ ¾à¹°À» »ç¿ëÇßÀ½¿¡µµ ºÒ±¸Ç졒ʡú·®ÀÇ °æ¿ì¿Í ¶È°°Àº ÁÖÀÛ¿ëÀÇ °úÀ×¹ßÇöÀ» Çϴ °æ¿ì ºÒ³»¼ºÀ̶ó°í ÇÑ´Ù. »ýü Ãø¿¡ ¾î¶°ÇÑ ÀáÀçÀû ÀåÇØ°¡ Á¸ÀçÇϰųª, ´Ù¸¥ ¾àǰÀ̳ª ±× Ã·°¡¹° µî°úÀÇ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ, ±× ¾à¹°ÀÇ Èí¼ö, ´ë»ç, ¹è¼³ µî¿¡ º¯È­°¡ ÀϾ, °á°úÀûÀ¸·Î ±× ¾à¹°ÀÇ Ç÷Áß³óµµÀÇ »ó½ÂÀ» ÃÊ·¡Çϱ⠶§¹®À̶ó°í »ý°¢µÈ´Ù.
¿µ¹® antihypertensive drug ÇÑ±Û °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
¼³¸í   
  °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇϸ砳ôÀº Ç÷¾ÐÀ» ³·Ãߴ ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃ۴ Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀǠȰµ¿À» ¾îµð¼±°¡ Â÷´ÜÇϴ ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù.
¿µ¹® antimalarial drug ÇÑ±Û ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
¼³¸í   
  ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Å°´Ï³×, Å¬·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼­ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼­ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ À־ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼­ÀǠȯ»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇϴ °Í(Ç×¹ø½Äü ¾àÀº Å¬·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Å¬·Î·Î±¸¾Æ³ªÀ̵å, Å°´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦Çϴ °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×À̴ °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇѠŸÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ È¯ÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯È­ÇÏÁö ¾Ê´Â´Ù.
¿µ¹® drug ÇÑ±Û ¾à, ¾à¹°, ¾àÁ¦
¼³¸í   
  1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½Ã۴ °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â È­ÇÕ¹°. ¾à¸®Çп¡¼­´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â È­Çй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °­ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼­·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ­, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, Ã¼Áß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ­´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í Àִ ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à.
¿µ¹® drug resistance ÇÑ±Û ¾à¹°³»¼º
¼³¸í   
  1. È­Çпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ È­Çпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼­ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈ­µÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ Àִ ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ Àִ ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇϸ頳»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼­ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇϴ °Í µîÀÌ ±× ¿¹ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alcoholic intolerance
    ¾ËÄڿøø°ßµõ(Áõ)
  • cold intolerance
    ÃßÀ§¸ø°ßµõ(Áõ)
  • carbohydrate intolerance
    ź¼öÈ­¹°¸ø°ßµõ(Áõ), ź¼öÈ­¹°ºÒ³»¼º
  • fatty food intolerance
    Áö¹æ½Ä¸ø°ßµõ(Áõ)
  • glucose intolerance
    Æ÷µµ´ç¸ø°ßµõ(Áõ), Æ÷µµ´çºÒ³»¼º
  • intolerance
    ¸ø°ßµõ(Áõ), ºÒ³»¼º
  • lactose intolerance
    Á¥´ç¸ø°ßµõÁõ, Á¥´çºÒ³»¼º
  • milk intolerance
    ¿ìÀ¯¸ø°ßµõ(Áõ)
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antianxiety drug
    Ç׺ҾÈÁ¦, ºÒ¾ÈÄ¡·áÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticancer drug
    Ç×¾ÏÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antidiabetic drug
    ´ç´¢º´¾à
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • intolerance
    ¸ø°ßµõ(Áõ)
  • cold intolerance
    ÇÑ·©¸ø°ßµõ(Áõ)
  • glucose intolerance
    Æ÷µµ´ç¸ø°ßµõ(Áõ), ´çºÒ³»¼º
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antiemetic drug
    ±¸Åä¾à, Ç×±¸ÅäÁ¦
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹ÎÁ¦
  • antihypertensive drug
    °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
  • antimalarial drug
    ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    Ç×±Õ¾à
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alcoholic intolerance
    ¾ËÄڿøø°ßµõ(Áõ)
  • carbohydrate intolerance
    ´çÁú¸ø°ßµõ(Áõ)
  • cold intolerance
    ÇÑ·©¸ø°ßµõ¼º
  • fatty food intolerance
    Áö¹æ½Ä¸ø°ßµõ(Áõ)
  • intolerance
    ¸ø°ßµõ(Áõ)
  • milk intolerance
    ¿ìÀ¯¸ø°ßµõ(Áõ)
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antianxiety drug
    ºÒ¾È¾à, Ç׺ҾÈÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticancer drug
    Ç×¾ÏÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antidiabetic drug
    ´ç´¢º´¾à
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fructose intolerance
    ÇÁ¶ôÅ佺ºÒ³»¼º
  • glucose intolerance
    Æ÷µµ´ç ºÒ³»¼º
  • hereditary fructose intolerance
    À¯Àü¼º ÇÁ·èÅä¿À½º ºÒ³»Áõ(¡­ÝÕÒ±ñø).
  • OTC drug : over-the-counter drug
    ÀϹݸžà.
  • ADR : adverse drug reaction
    ¾à¹°À¯ÇØÀÛ¿ë(å·ÚªêóúªíÂéÄ).
  • IND : investigational new drug
    ½ÃÇè¿ë½Å¾à.
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£Ç¥Çö
  • NDA : new drug application
    ½Å¾àÇã°¡½Åû.
  • TDM : therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ ¸ð´ÏÅ͸µ.
  • addiction, drug
    ¸¶¾à»ó½À(ئå·ßÈã§)
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°ÈïºÐ¾à, ¾Æµå·¹³¯¸°ÀÚ±ØÁ¦.
  • adulterated drug
    ¼¯À½Áú¾àǰ.[¿¹¹æ]ºÎÁ¤¾àǰ(ËÓËøËâ̰).
  • allergy, drug
    ¾à¹°¾Ë·¹¸£±â
  • antiallergic agent =a. drug
    Ç׾˷¹¸£±â¾à.
  • antiallergic drug
    Ç׾˷¹¸£±â¾à.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alcoholic intolerance
    ¾ËÄڿúҳ»¼º(¡­ÝÕÒ±àõ).
  • carbohydrate intolerance
    ´çÁúºÒ³»¼º(ÓØòõÝÕÒ±àõ)
  • cold intolerance
    ÇÑ·©ºÒ³»¼º
  • familial fructose and galactose intolerance
    °¡Á·¼º ÇÁ·°Åä¿À½º ¹× °¥¶ôÅä ¿À½º ºÒ³»Àμº(¡­ÝÕÒ±ìÑàõ).
  • fatty food intolerance
    Áö¹æ½ÄºÒ³»¼º(¡­ãÝÝÕÒ±àõ).
  • fructose intolerance
    ÇÁ¶ôÅ佺ºÒ³»¼º
  • glucose intolerance
    Æ÷µµ´ç ºÒ³»¼º
  • hereditary fructose intolerance
    À¯Àü¼º ÇÁ·èÅä¿À½º ºÒ³»Áõ(¡­ÝÕÒ±ñø).
  • intolerance
    °ü¿ë
  • lactose intolerance
    ¶ôÅä¿À½ººÒ³»Áõ (¡­ÝÕÒ±ñø).
  • milk intolerance
    ¿ìÀ¯ºÒ³»¼º
  • milk intolerance
    ¿ìÀ¯ºÒ³»Áõ.
  • sucrose intolerance
    (ÀÚ)½´Å©·Î½º°ÅºÎÁõ.
  • drug dependence ; drug dependency
    ¾à¹°ÀÇÁ¸(¼º).
  • addiction, drug
    ¸¶¾à»ó½À(ئå·ßÈã§)
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antiamebic drug
    ¾Æ¸Þ¹Ù±¸ÃæÁ¦
  • antimalarial drug
    Ç׸»¶ó¸®¾ÆÁ¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fructose intolerance
    ÇÁ¶ôÅ佺 °ÅºÎÁõ(ËÞÜúñø)
  • lactose intolerance
    ¶ôÅ佺°ÅºÎÁõ(ËÞÜúñø)
  • lysine intolerance
    ¶óÀ̽ŰźÎÁõ(ËÞÜúñø)
  • milk intolerance
    Á£ °ÅºÎÁõ(ËÞÜúñø)
  • sucrose intolerance
    ½´Å©·Î½º °ÅºÎÁõ(ËÞÜúñø)
  • drug-detoxication enzyme
    ¾à¹°Çص¶ È¿¼Ò(å·Úªú°Ô¸ý£áÈ) (ÔÒ) drug-metabolizing enzyme
  • drug-metbolizing enzyme
    ¾à¹°´ë»ç È¿¼Ò(å·ÚªÓÛÞóý£áÈ)
  • drug resistance
    ¾à¹° ÀúÇ×(å·Úªî½ù÷)
  • drug-resistance plasmid
    ¾à¹°ÀúÇ×(å·Úªî½ù÷) Çö󽺹̵å (ÔÒ) R plasmid
  • narcotic drug
    ¸¶¾à(ئå·)
  • psychedelic drug
    ȯ°¢Á¦(ü³ÊÆð¥)
  • radiomimetic drug
    ¹æ»ç¼± ¾ç(À¯»ç) ¾à¹°(Û¯ÞÒàÊåÆ(ëºÞÄ)å·Úª)
  • sulfa drug
    ¼³ÆÄÁ¦(ð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • drug abuse
    ¾à¹°³²¿ë
  • narcotic drug
    ¸¶¾à
  • tuberculostatic drug
    Ç×°áÇÙ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DA dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis...
AMI acquired monosaccharide intolerance; acute myocardial infarction; amitriptyline; anterior myocardial...
ASA acetylsalicylic acid; active systemic anaphylaxis; Adams-Stokes attack; American Society of Anesthes...
FCI fixed-cell immunofluorescence; food chemical intolerance
FI fasciculus intrafascicularis; fever caused by infection; fibrinogen; fixed interval; flame ionizatio...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CMPI Cow's Milk Protein Intolerance
HFI Hereditary Fructose Intolerance
LPI Lysinuric protein intolerance
OI Orthostatic Intolerance
ADAP AIDS Drug Assistance Program
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • carbohydrate intolerance
    ´çÁú ºÒ³»¼º
  • cold intolerance
    ÇÑ·© ºÒ³»¼º
  • heat intolerance
    ³»¿­¼º
    ¿­¿¡ °ßµð´Â ¼ºÁú.
  • orthostatic intolerance
    ±â¸³¼º Á¶Àý Àå¾Ö
    ´¯°Å³ª Àå½Ã°£ ¾É¾Æ ÀÖ´Ù°¡ °©ÀÚ±â ÀϾ ¶§ ³ú, ½ÉÀå µîÀÇ Ç÷·ù°¡ °¨¼ÒÇÏ¿© Çö±âÁõ, ±¸Åä, ½É°è Ç×Áø, ÀÇ½Ä »ó½Ç µîÀÌ ÀϾ´Â Áõ¼¼. ±â¸³¼º Çö±âÁõÀ̶ó°íµµ ÇÑ´Ù. Á¤»óÀÎÀÎ °æ¿ì¿¡´Â ±â¸³ ½Ã¿¡ ¸»ÃÊÇ÷°üÀÌ ¼öÃàÇϸ鼭 Ç÷¾Ð, ¼øÈ¯ Ç÷·®À» À¯Áö½ÃŰ·Á´Â ±âÀüÀÌ ÀÖÀ¸³ª, ÀúÇ÷¾ÐÁõ, ÀÚÀ²½Å°æ ½ÇÁ¶ ¹× ³úÇϼöü, »ý½Ä¼± µîÀÇ ±â´É¿¡ ÀÌ»óÀÌ ÀÖÀ» °æ¿ì, ±âÀü¿¡ Àå¾Ö°¡ ¹ß»ýÇÏ¿© ÀÌ Áõ¼¼¸¦ °¡Á®¿Â´Ù.
  • addicting drug
    ½À°ü¼º ¾à
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • anesthetic drug
    ¸¶Ãë ¾à
  • antagonistic drug
    ±æÇ× ¾à, ±æÇ×Á¦
  • antiamebic drug
    Ç׾Ƹ޹٠¾à
    ¾Æ¸Þ¹Ù¸¦ »ì¸ê ¶Ç´Â ¹ßÀ°À» ¾ïÁ¦ÇÏ´Â ¾à¹°.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • anticancer drug
    Ç×¾ÏÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
    Ç÷¾×ÀÇ ÀÀ°í¸¦ ¸·´Â ¾àÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´ Ä¡·á ¾à
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
drug-drug interaction The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity.
(09 Oct 1997)
glucose intolerance A pathological state in which the fasting plasma glucose level is less than 140 mg per deciliter and the 30-, 60-, or 90-minute plasma glucose concentration following a glucose tolerance test exceeds 200 mg per deciliter. This condition is seen frequently in diabetes mellitus but also occurs with other diseases.
(12 Dec 1998)
hereditary fructose intolerance A metabolic error due to deficiency of hepatic fructose 1,6-bisphosphate aldolase B (which also acts on fructose 1-phosphate); the second enzyme in the specific fructose pathway; vomiting and hypoglycaemia follow ingestion of fructose; prolonged fructose ingestion in young children results in failure to thrive and in jaundice, hepatomegaly, albuminuria, aminoaciduria, and sometimes cachexia and death; autosomal recessive inheritance in most families.
(05 Mar 2000)
intolerance Inability to withstand, sensitivity, as to a drug.
Origin: L. Tolerare = to bear
(18 Nov 1997)
lactose intolerance A disorder characterised by abdominal cramps and diarrhoea after the consumption of food containing lactose (for example milk, ice cream), believed to occur due to a deficiency of intestinal lactase (enzyme that breaks down lactose), may appear first in young adults who have previously tolerated milk well as infants.
(27 Sep 1997)
fructose intolerance An autosomal recessive fructose metabolism disorder due to deficient fructose-1-phosphate aldolase (ec 2.1.2.13) activity, resulting in accumulation of fructose-1-phosphate. The accumulated fructose-1-phosphate inhibits glycogenolysis and gluconeogenesis, causing severe hypoglycaemia following ingestion of fructose. Prolonged fructose ingestion in infants leads ultimately to hepatic failure and death. Patients develop a strong distaste for sweet food, and avoid a chronic course of the disease by remaining on a fructose- and sucrose-free diet.
(12 Dec 1998)
lysinuric protein intolerance An autosomal recessive disorder characterised by elevated levels of dibasic amino acids (e.g., l-lysine, l-arginine, and l-ornithine) in the urine; apparently due to a defect in dibasic amino acid transport.
(05 Mar 2000)
abnormalities, drug-induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
(12 Dec 1998)
activity, drug A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa).
(12 Dec 1998)
addictive drug Any drug that creates a certain degree of euphoria and has a strong potential for addiction.
(05 Mar 2000)
adverse drug reaction reporting systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
(12 Dec 1998)
akathisia, drug-induced Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation).
(12 Dec 1998)
antineoplastic drug A drug that stops or slows the maturation and spread of tumour cells (benign or malignant).
(09 Oct 1997)
maintenance drug therapy In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
rational drug design <pharmacology> Modeling the molecular structure of the target of a drug, for example, an antigen, and then designing a drug that will attack it.
(17 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • intolerance
    µµ·®ÀÌ Á¼Àº
  • intolerance
    ÂüÀ»¼ö ¾øÀ½;¾Æ·®ÀÌ ¾øÀ½;¿ËÁ¹;ÆíÇù(narrowmindedness)
  • Food and Drug Administration
    ½Äǰ ÀǾ౹(º¸°Ç ±³À° º¹Áö¼ºÀÇ ÀϺÎ)
  • combination drug
    º¹ÇÕ¾à(2Á¾ ÀÌ»óÀÇ Ç×»ý ¹°Áú µîÀÇ È¥ÇÕ¾à)
  • counter drug
    ÀÇ»çÀÇ Ã³¹æ ¾øÀÌ ÆÇ¸ÅµÇ´Â ¾à
  • drug
    ¾à;¾àÁ¦;¾àǰ;¸¶¾à;~¿¡ ¾àÀ»³Ö´Ù;¸¶Ãë½ÃŰ´Ù;¹°¸®°ÔÇÏ´Ù
  • drug addict
    ¸¶¾à Áßµ¶ÀÚ
  • drug buster
    (¹Ì)¸¶¾à ´Ü¼Ó°ü 
  • drug design
    (¾à)¾àÁ¦ ¼³°è(À¯È¿¼ºÀ» ³ôÀ̱â À§ÇÑ Á¾ÇÕÀû °³¹ß °ËÅä
  • drug interaction
    (¾à)¾à¹° »óÈ£ ÀÛ¿ë
  • drug pump
    (ÀÇ)¾à ÆßÇÁ(Ç÷°ü ÁÖ»ç¿ë)
  • fertillity drug
    ÀӽŠÃËÁøÁ¦
  • garbage drug
    ¿ªÈ¿°ú¸¦ ÃÊ·¡Çϱ⠽¬¿î ¸¶¾à(Á¢ÂøÁ¦³ª ½Ã³Ê µî)
  • hard drug
    ½À°ü¼º ¸¶¾à
  • miracle drug
    Ưȿ¾à;¿µ¾à
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á